Status:
COMPLETED
Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Conditions:
Biliary Cancer
Cholangiocarcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study evaluates the combination chemotherapy with gemcitabine, irinotecan and panitumumab in patients with advanced biliary cancer.
Eligibility Criteria
Inclusion
- histologically or cytologically confirmed local advanced unresectable/metastatic adenocarcinoma of biliary tract
- measurable disease
- available tumor tissue for investigational immunohistochemical evaluations
- ECOG PS 0-2
- No prior chemotherapy, biologic therapy or radiation therapy
- Age Eighteen and older
- Lab values per protocol
Exclusion
- Life expectancy less than three months
- Concurrent use of chemotherapy not indicated in the study protocol or any other investigational agents and patients who have received investigational drugs less than four weeks prior to enrollment
- Prior therapy, which affects or targets the EGF pathway
- Treatment for other carcinomas within the last five years, except cured non-melanoma skin and treated in-situ cervical cancer
- Recovery from major surgery within three weeks of the start of study treatment
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 26 2014
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00948935
Start Date
April 1 2009
End Date
September 26 2014
Last Update
March 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104